We help clients assess chemical compound safety to develop safer and more effective pharmaceuticals, food ingredients, agricultural chemicals, commodity chemicals, and consumer products. At the frontline of next generation risk assessment (NGRA), we develop customized cell-based assays to determine safety, model chemical disposition in the body, and analyze and interpret genetic data. Our solutions save our clients time and money by bringing their products to market faster.
Latest News (See all)
Jake Reske, ScitoVation graduate intern in toxicogenomics, will explains a meta-analysis strategy used to develop a preliminary classifier of hepatic cholestasis through public transcriptomic data sets. Cholestasis is a hepatic disease that… Read more »
Dr. Kareen Coulombe joined us to share her latest findings for assessing cardiac toxicity using a predictive 3D human cardiac microtissue platform for assessing toxicity of chemical compounds. What you’ll… Read more »
ScitoVation and BioSpyder are excited to introduce our new transcriptomics analysis package, ScitoXpress™. ScitoXpress™ provides important information about points of departure (POD) and potential modes of action (MoA) for our clients’ compounds. ScitoXpress™ characterizes chemical risk cost-efficiently and rapidly.
Because changes in gene expression precede changes in phenotype, a robust transcriptomics package like ScitoXpress™ can provide answers at lower doses compared to disease or tumor endpoints are typical used in in vivo studies. ScitoXpress™ offers the additional advantages of:
- Providing utility in guiding additional studies, resulting in cost- and time-savings
- Being based on a rigorous scientific approach, applied by experts
- Having the support of U.S. EPA
Who We Serve
By combining modern biological and computational methods, we help our clients develop safer and more effective pharmaceuticals, food ingredients, agricultural chemicals, commodity chemicals and consumer products.
by Patrick McMullen ScitoVation has a long history of innovation and application of high-content data streams in toxicology. Omics technologies, screening platforms, and high-content imaging can all be used to… Read more »
by Marjory Moreau As an advocate for PBPK modeling in risk assessment, I want to share with you how PBPK modeling can be used to address vulnerable populations. We all know that individuals won’t respond the same way to chemical… Read more »
by Jeff Fisher Edited by Donald Mattison Lee-Ann Halbert I was the senior author of one chapter in the newly released textbook, “Clinical Pharmacology During Pregnancy, second edition.” Coauthors on the original research publications include scientists from the US FDA, Duke University,… Read more »